. 2018 Jul 5;7(8):914–923. doi: 10.1530/EC-18-0172
This work is licensed under a Table 1.
Baseline patient demographic and auxological data for patients treated with GH using easypod, overall and for the subgroup who were GH naïve at the start of easypod use.
| Overall analysis population (n = 1203) | GH-naïve population (n = 610) | |
|---|---|---|
| Age, years (min; max) | 10 (1; 19) | 10 (1; 19) |
| Sex, n (%) | ||
| Female | 503 (41.8) | 238 (39.0) |
| Male | 700 (58.2) | 372 (61.0) |
| Ethnicity, n (missing) | 1185 (18) | 593 (17) |
| African, n (%) | 9 (0.7) | 4 (0.7) |
| Asian, n (%) | 195 (16.2) | 108 (17.7) |
| Caucasian, n (%) | 822 (68.3) | 367 (60.2) |
| Other, n (%) | 159 (13.2) | 114 (18.7) |
| Missing | 18 (1.5) | 17 (2.8) |
| Pubertal stage, n (missing) | 490 (713) | 573 (37) |
| Tanner 1, n (%) | 335 (68.3) | 416 (72.6) |
| Tanner >1, n (%) | 155 (21.7) | 157 (27.4) |
| IGF1 status, n (missing) | 390 (813) | 109 (501) |
| Abnormal low, n (%) | 51 (13.1) | 13 (11.9) |
| Normal, n (%) | 300 (76.9) | 88 (80.7) |
| Abnormal high, n (%) | 39 (10.0) | 8 (7.3) |
| Bone age, n (missing) | 207 (996) | 507 (103) |
| Greulich and Pyle assessment (years) | 10.0 (6.0; 12.0) | 8.0 (5.0; 10.6) |
| Growth velocity (cm/year) | 4.6 (3.3; 5.1) | 4.0 (3.3; 5.1) |
| Height (cm) | 121.1 (103.2; 134.4) | 122.8 (106.3; 135.0) |
| Indication for GH treatment, n (%) | ||
| GHD | 897 (74.6) | 499 (81.8) |
| SGA | 207 (17.2) | 67 (11.0) |
| Turner syndrome | 82 (6.8) | 37 (6.1) |
| Other | 17 (1.4) | 3 (0.5) |
Unless specified, values are presented as median (Q1; Q3) or number of patients (% of total).
CAS, complete analysis set; GH, recombinant human growth hormone; GHD, growth hormone deficiency; IGF1, insulin-like growth factor-1; SGA, small for gestational age.